Category: MassDevice sales & earnings roundup

Accuray gives conservative forecast for 2011

August 31, 2010 by MassDevice staff

Accuray Inc. (NSDQ:ARAY) is starting 2011 with a sizable hole in its top line that will hamper sales growth and profits over the next year, company officials said in a conference call with analysts.

Angeion's Q3 sales jump 14 percent as it swings from loss to profit

August 25, 2010 by MassDevice staff

Angeion Corp. (NSDQ:ANGN) put some black ink in the ledger book during the third quarter, as a 14 percent sales increase pushed it to profitability.

The St. Paul, Minn.-based cardiorespiratory diagnostic equipment maker posted net income of $126,000, or 3 cents per diluted share, on sales of $7.1 million during the three months ended July 31. That compares with a net loss of $173,000, or 4 cents per diluted share, on sales of $6.2 million during the same period last year.

Synovis swings to Q3 black

August 25, 2010 by MassDevice staff

Synovis Life Technologies Inc. (NSDQ:SYNO) swung into the black on strong sales growth during the third quarter.

The St. Paul, Minn.-based company reported net earnings of $1.5 million, or 13 cents per diluted share, on revenue of $17.6 million during the three months ended June 30. That compares with a net loss of $4.9 million, or 42 cents per diluted share, on sales of $15 million during the same period last year.

CEO Richard Kramp credited the company's year-old investment in its direct sales force for the improvement.

Urologix pares Q4, 2010 losses

August 24, 2010 by MassDevice staff

Urologix Inc. (NSDQ:ULGX) pared its fourth-quarter and full-year losses and boosted its fiscal 2010 top line by 15.3 percent, despite a delay in Medicare reimbursements that helped push fourth-quarter sales down 5.4 percent.

The Minneapolis-based medical device maker posted net losses of $622,000, or 4 cents per diluted share, on sales of $3.3 million during the three months ended June 30. That compares with net losses of $875,000, or 6 cents per diluted share, on sales of $3.4 million during the same period last year.

Echo Therapeutics closes trial, preps for FDA submission in the "near future"

August 24, 2010 by MassDevice staff

Echo Therapeutics Inc. (OTC:ECTE) announced the completion of a clinical trial of its Prelude SkinPrep transdermal drug delivery system, saying an application for 510(k) clearance from the Food & Drug Administration is imminent.

The Franklin, Mass.-based company launched the trial in April, in partnership with Ferndale Pharma Group Inc., to test the drug-device combination with Ferndale's 4 percent topical lidocaine. The needle-free system ablates a thin layer of skin before a drug is applied.

Medtronic posts lower Q1 sales, lowers guidance

August 24, 2010 by MassDevice staff

Medtronic Inc. (NYSE:MDT) managed to post significant top-line gains despite a slight decline in first-quarter sales, largely due to a shorter start to fiscal 2011.

The Fridley, Minn.-based medical device monolith reported profits of $830 million, or 76 cents per diluted share, on sales of $3.77 billion during the three months ended July 30. That compares with profits of 445 million, or 40 cents per diluted share, on sales of $3.93 billion during the same period last year.

Kensey Nash's Q4 net soars, but 2010 earnings tick down

August 23, 2010 by MassDevice staff

Kensey Nash Corp. (NSDQ:KNSY) closed fiscal 2010 with a robust fourth quarter, but posted modest declines in both sales and earnings for fiscal 2010.

Kensey Nash reported net income of $5.9 million, or 60 cents per diluted share, on sales of $21.9 million during the three months ended June 30. That compares with profits of $4.7 million, or 41 cents per diluted share, on sales of $20.5 million during Q4 2009.